Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington’s Disease Patients
- 29 janvier 2025 - 1 mn de lecture
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BN82451B versus placebo after oral administration twice daily (bid) for 28 days in patients with Huntington’s Disease (HD).
29 janvier 2025
1 mn de lecture
Evaluation of the Effect of Psycho-oncological Intervention on Well-being of Patients With Advanced Prostate Cancer on LHRH Analogs and Their Partners. A Randomized Controlled Pilot...
29 janvier 2025
1 mn de lecture
Study to Assess the Efficacy and Safety of Dysport® in the Treatment of Chronic Plantar Fasciitis
29 janvier 2025
1 mn de lecture
Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET
29 janvier 2025
1 mn de lecture
Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly
29 janvier 2025
1 mn de lecture
Equivalence of Intramuscular (IM) Versus Subcutaneous (SC) Applications of Long Acting Pamorelin 11.25 mg
29 janvier 2025
1 mn de lecture
Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients
29 janvier 2025
1 mn de lecture
Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.
29 janvier 2025
1 mn de lecture
Quality of Life in Patients With Inoperable Malignant Bowel Obstruction
29 janvier 2025
1 mn de lecture
Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours
29 janvier 2025
1 mn de lecture